{
  "Variants Include": [
    {
      "Gene": "SNCA",
      "variants": [
        {
          "HGVS": "NM_000340.3:c.158C>T",
          "cDNA Change": {
            "transcript": "NM_000340.3",
            "ref": "C",
            "alt": "T",
            "position": "158"
          },
          "Protein Change": {
            "ref": "A",
            "alt": "T",
            "position": "53"
          },
          "Description in input context": "A53T mutation in alpha-synuclein (SNCA) associated with Parkinson's disease"
        },
        {
          "HGVS": "NM_000340.3:c.90C>T",
          "cDNA Change": {
            "transcript": "NM_000340.3",
            "ref": "C",
            "alt": "T",
            "position": "90"
          },
          "Protein Change": {
            "ref": "A",
            "alt": "P",
            "position": "30"
          },
          "Description in input context": "A30P mutation in alpha-synuclein (SNCA) associated with Parkinson's disease"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's disease",
    "MONDO": "MONDO:0005215"
  },
  "Experiment Method": [
    {
      "Assay Method": "Immunohistochemistry",
      "Material used": {
        "Material Source": "Human brain tissue",
        "Material Name": "Postmortem brain samples from Parkinson's patients",
        "Description": "Alpha-synuclein aggregation was analyzed in postmortem brain samples from Parkinson's disease patients carrying the A53T mutation."
      },
      "Readout type": "Qualitative",
      "Readout description": [
        {
          "Variant": "NM_000340.3:c.158C>T",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Increased aggregation",
          "Result Description": "A53T mutation showed significant alpha-synuclein aggregation in Lewy bodies compared to wild-type."
        },
        {
          "Variant": "NM_000340.3:c.90C>T",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Enhanced fibrillization",
          "Result Description": "A30P mutation led to more pronounced alpha-synuclein fibrillization in brain tissue."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "N.D."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "N.D."
      },
      "Basic positive control": {
        "Basic positive control": "N.D.",
        "Description": "N.D."
      },
      "Basic negative control": {
        "Basic negative control": "N.D.",
        "Description": "N.D."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Normal alpha-synuclein solubility and no aggregation",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Significant aggregation or fibrillization detected",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "Western Blot",
      "Material used": {
        "Material Source": "Cell line",
        "Material Name": "HEK293 cells overexpressing mutant alpha-synuclein",
        "Description": "HEK293 cells were transfected with plasmids encoding A53T or A30P variants of alpha-synuclein."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_000340.3:c.158C>T",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Reduced solubility",
          "Result Description": "A53T variant showed 40% reduction in soluble alpha-synuclein levels compared to wild-type."
        },
        {
          "Variant": "NM_000340.3:c.90C>T",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Increased insoluble fraction",
          "Result Description": "A30P variant had 60% increase in insoluble alpha-synuclein compared to controls."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Three biological replicates were conducted for each variant."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Each sample was analyzed in triplicate."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type alpha-synuclein was used as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "Empty vector-transfected cells served as negative controls."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "Yes",
        "Counts": "2"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "No",
        "Counts": "0"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "Student's t-test was used to compare mutant vs. wild-type groups."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Soluble alpha-synuclein levels > 70% of wild-type",
        "Source": "Literature"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Soluble alpha-synuclein levels < 50% of wild-type",
        "Source": "Literature"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "In vitro fibrillation assay",
      "Material used": {
        "Material Source": "Recombinant protein",
        "Material Name": "Purified human alpha-synuclein variants",
        "Description": "Fibrillation kinetics were measured for A53T and A30P variants under physiological conditions."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_000340.3:c.158C>T",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Accelerated fibrillation",
          "Result Description": "A53T variant formed fibrils 2.5 times faster than wild-type alpha-synuclein."
        },
        {
          "Variant": "NM_000340.3:c.90C>T",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Increased stability of fibrils",
          "Result Description": "A30P variant showed 30% greater fibril stability compared to wild-type."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "N.D."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "N.D."
      },
      "Basic positive control": {
        "Basic positive control": "N.D.",
        "Description": "N.D."
      },
      "Basic negative control": {
        "Basic negative控制": "N.D.",
        "Description": "N.D."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Fibrillation time > 18 hours",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Fibrillation time < 12 hours",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}